We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+12.84%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.59B
AUM Growth
-$301M
(-6.2%)
Cap. Flow
-$430M
Cap. Flow
% of AUM
-9.37%
Top 10 Holdings %
Top 10 Hldgs %
42.8%
Holding
130
New
21
Increased
24
Reduced
35
Closed
20
Top Buys
| 1 |
AstraZeneca
AZN
|
+$129M |
| 2 |
Merck
MRK
|
+$76.6M |
| 3 |
Guardant Health
GH
|
+$43.7M |
| 4 |
Mineralys Therapeutics
MLYS
|
+$31.5M |
| 5 |
uniQure
QURE
|
+$28.3M |
Top Sells
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$87M |
| 2 |
Eli Lilly
LLY
|
+$65.3M |
| 3 |
APLS
Apellis Pharmaceuticals
APLS
|
+$61M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$57.8M |
| 5 |
Cigna
CI
|
+$56.4M |
Sector Composition
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Edgewise Therapeutics
EWTX
$4.27B
| $489M | 10.66% |
15,518,492
| – | – |
|
2
Enliven Therapeutics
ELVN
$3.7B
| $312M | 6.8% |
7,959,538
| – | – |
|
|
3
Eli Lilly
LLY
$1.03T
| $218M | 4.75% |
236,800
-64,400
| -21% | -$65.3M |
|
|
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
| $184M | 4.02% |
2,718,735
| – | – |
|
5
Boston Scientific
BSX
$63.4B
| $149M | 3.26% |
2,382,100
-37,200
| -2% | -$2.98M |
|
|
SION
6
Sionna Therapeutics
SION
$1.92B
| $142M | 3.09% |
3,530,702
-30,953
| -0.9% | -$1.18M |
|
|
7
AstraZeneca
AZN
$255B
| $132M | 2.88% |
+670,200
| New | +$129M |
|
8
Myriad Genetics
MYGN
$570M
| – | – |
0
| – | – |
|
|
MBX
9
MBX Biosciences
MBX
$2.69B
| $109M | 2.37% |
3,637,887
-297,316
| -8% | -$10.1M |
|
10
Corvus Pharmaceuticals
CRVS
$1.26B
| $105M | 2.29% |
7,165,006
| – | – |
|
11
argenx
ARGX
$53.8B
| $100M | 2.18% |
136,900
-9,100
| -6% | -$7.12M |
|
12
Edwards Lifesciences
EW
$51.9B
| $98.5M | 2.15% |
1,230,600
-612,300
| -33% | -$50.5M |
|
13
Intuitive Surgical
ISRG
$134B
| $96.2M | 2.1% |
208,700
-54,700
| -21% | -$27.7M |
|
14
Compass Therapeutics
CMPX
$394M
| $80.5M | 1.76% |
15,219,994
| – | – |
|
|
15
Merck
MRK
$298B
| $79.8M | 1.74% |
+663,400
| New | +$76.6M |
|
16
Structure Therapeutics
GPCR
$3.6B
| $71.1M | 1.55% |
1,475,403
+313,600
| +27% | +$21.5M |
|
17
ArriVent BioPharma
AVBP
$1.52B
| $69.8M | 1.52% |
3,027,328
| – | – |
|
18
Disc Medicine
IRON
$2.87B
| $68.3M | 1.49% |
1,067,550
| – | – |
|
19
ARS Pharmaceuticals
SPRY
$756M
| $66.6M | 1.45% |
8,288,510
| – | – |
|
20
CG Oncology
CGON
$6.33B
| $64.2M | 1.4% |
948,267
-568,283
| -37% | -$32.2M |
|
21
Xenon Pharmaceuticals
XENE
$6.51B
| $61.6M | 1.34% |
1,059,971
+612,771
| +137% | +$28.2M |
|
22
Stryker
SYK
$119B
| $60M | 1.31% |
182,500
-142,500
| -44% | -$51.2M |
|
23
Bristol-Myers Squibb
BMY
$116B
| $56.1M | 1.22% |
925,000
+150,000
| +19% | +$8.74M |
|
|
24
Mineralys Therapeutics
MLYS
$2.4B
| $55.6M | 1.21% |
2,052,900
+1,072,500
| +109% | +$31.5M |
|
25
Praxis Precision Medicines
PRAX
$9.14B
| $55.6M | 1.21% |
172,500
+78,000
| +83% | +$24.1M |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM